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After a right thalamic stroke, an 86-year-old man pre-
sented an acute pure left representational neglect in the
absence of any perceptual neglect. On spatial mental im-
agery tasks, the patient systematically omitted items lo-
cated on his left side, but only when a vantage point was
given. This suggests that (1) pure representational neglect
is not just a residual finding after recovery from global
(perceptual and representational) neglect; (2) space rep-
resentation can be coded by two independent processes:
in viewer-centered or world-based (allocentric) coordi-
nates; and (3) the right thalamus serves as a relay in the
processing of spatial visual imagery.
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Unilateral neglect is generally defined as an impaired
ability to detect stimuli in the contralesional hemis-
pace. Neglect can occur when a patient actually sees
environmental space (perceptual neglect), but also
when he imagines the space without being there (rep-
resentational neglect).1
Left and right hemispace can be defined with respect
to viewer-centered and environment-centered or
object-centered (allocentric) frames of reference.2
Viewer-centered coordinates involve the ability to lo-
cate objects with reference to the subject’s own body,3
whereas allocentric coordinates determine where some-
thing lies in the world with reference to the environ-
ment itself.4 The allocentric frame of reference implies
that relationships among multiple landmarks are coded
and stored independently of the position of the sub-
ject’s body. Perceptual neglect is typically based on
viewer-centered frames of reference,5 although relative
environment-centered coordinates may also be in-
volved.6,7 Representational neglect may similarly in-
volve both viewer-centered and allocentric coordinates;
mental imagery could preferentially operate on stored
representations independent of the viewer position.
However, to our knowledge, viewer-centered and allo-
centric coordinate frames have not yet been dissociated
in representational neglect. Pure representational ne-
glect, confined to internally generated representations
of visual images8–11 is much less frequent than percep-
tual neglect with1,12–15 or without2,8,12 representa-
tional neglect. Because in 1 patient, representational
neglect appeared as a pure deficit only after an initially
concomitant perceptual neglect recovered, representa-
tional neglect has been considered as a dynamic phe-
nomenon of recovery from a global (perceptual and
representational) neglect syndrome.12 Finally, there is
also evidence that representational and perceptual ne-
glect might be dissociated with respect to lesion loca-
tion.8,9 However, pure representational neglect has
only been described following cortical lesions. Here, we
describe a patient who presented a pure left represen-
tational neglect following a right thalamic infarction.
Patient and Methods
This 86-year-old right-handed man suffered from an acute
onset of dysarthria and a moderate left hemiparesis without
hemisensory loss, which recovered completely within 2
weeks. Magnetic resonance imagine (MRI) 1 week after ad-
mission showed a recent right thalamic ischaemic lesion in
the dorsomedial nucleus of the thalamus extending into the
pulvinar (Fig 1).
On admission, the patient was oriented and aware of his
motor deficit. A detailed neuropsychological examination on
the fifth day was normal except for impairment in figural
fluency16 and a strong left representational neglect. There
was no perceptual neglect and no tactile, auditory, or visual
extinction. Mental imagery outside the spatial domain was
unaffected: drawing and verbal description from memory of
objects and animals, oral spelling tasks, and a body imagery
test10 were flawless. All tasks were administrated on several
occasions from the fifth day after admission.
A general neuropsychological examination revealed that
the patient had no aphasic deficit and no clinical deficit in
long-term memory (percentile 50 on the Buschke Selective
Reminding Test; percentile 10 on Rey’s signs). In short-term
memory, his scores were in the normal range (percentile 75
on the digit span; percentile 50 on the Corsi block-span).
His performance was in the lower range (percentile 25) on
the Topographical Recognition Memory subtest of the Cam-
den Memory Tests, and in the normal range in the Benton
Visual Discrimination Test (41 of 54).
Assessment of Perceptual Neglect
In order to examine neglect in extrapersonal space,17 four
different tasks were given both in near (NS) and far (FS)
space18: a line bisection task and three cancellation tasks with
letters, digits, or lines. In addition, other tasks were given in
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the NS condition including a landscape copying task, a star
cancellation task, clock copying task, word (n 5 10 per con-
dition) and sentence (n 5 3 per condition) reading in hor-
izontal, vertical, and mirror (only for words) positions.
Assessment of Representational Neglect
In order to dissociate the representational frames of refer-
ence, two different conditions, involving viewer-centered and
allocentric spatial coordinates were administrated in a coun-
terbalanced order. Performance remained stable during the
whole period of investigation.
VIEWER-CENTERED CONDITION. The patient was asked
to mentally visualize a familiar square: the Place Neuve in
Geneva (local version of Bisiach’s test1). Using four different
given vantage points (Fig 2A–C), he had to describe and to
draw the Place Neuve from memory, imagining he could
only move the head and the eyes from right to left and left
to right but not walk.
Vantage points included conditions emphasizing viewer-
centered imagery: (1) facing the theatre with his back against
the park gate; (2) back against the theatre’s door facing the
park gate (opposite position); (3) his right shoulder against
the park gate, so that the entire square is on the left side of
his body; and (4) his left shoulder against the park gate (in-
verse position).
In a second task, he was asked to list all the towns he
could mention on the Swiss coast of the lake of Geneva, as
seen from a hypothetical vantage point on the opposite
French coast (see Fig 2E). He had to imagine himself in
Evian (a French city along the lake), looking toward Lau-
sanne (a Swiss city facing Evian).
The patient’s responses were recorded in the two tasks and
compared with his performance in the allocentric condition,
which could thus serve as his own control.
ALLOCENTRIC CONDITION (WORLD-CENTERED). The
patient was asked to draw and to describe a maplike repre-
sentation of the Place Neuve without requiring any specific
vantage point (see Fig 2D). He was told: “Describe the Place
Neuve as you would explain it to a tourist.” Again, in a sec-
ond task, his topographical knowledge of the lake of Geneva
was assessed by asking him to give the maximum of names of
Fig 2. (A and B) Maps of a familiar square verbally
described from mental imagery (viewer-centered condition).
Vantage points are indicated by squares with an arrow
pointing in the viewing direction. Black digits refer to the
details reported from vantage points indicated with black
squares and black arrows, while white digits refer to the
details reported from opposite vantage points indicated with
white squares and white arrows. Digits indicate the order in
which the details were reported. (C) Patient’s drawing
corresponding to the vantage point indicated with black
square and black arrow in B. (D) Patient’s drawing of the
square without an imposed vantage point, demonstrating his
preserved recall in the allocentric condition. (E) Cities along
the lake of Geneva reported when a vantage point (black
square and black arrow) was given (viewer-centered
condition). (F) Cities reported without an imposed vantage
point (allocentric condition).
Fig 1. Brain magnetic resonance imaging performed on the
ninth day after hospitalization. Axial T2-weighted MR image
showing a right thalamic lesion including the dorsomedial
nucleus and the pulvinar.
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cities along the lake between Geneva and Villeneuve, two
cities located at both extremities of the lake (see Fig 2F).
Results
Assessment of Perceptual Neglect
Performance was flawless in all NS (mean deviation 5
13mm 4) and FS (mean deviation 5 13mm 4) con-
ditions. There was no significant deviation in line bi-
section. There was no omission in the cancellation
tasks. Exploration of the visual stimuli during the can-
cellation tasks was indifferently started from the left or
right side of paper sheets, revealing no consistent spa-
tial bias overall. Copying and reading tasks were not
impaired by neglect-related errors.
Assessment of Representational Neglect
VIEWER-CENTERED CONDITION. A strong representa-
tional neglect was observed in the different imagery
tasks in the viewer-centered condition. When asked to
describe or to draw the Place Neuve, the patient sys-
tematically omitted elements on the left of his imagi-
nary self-position (Table, see Fig 2A–C). In the second
task, five cities were named on the right side of the
lake of Geneva, versus none on the left (see Fig 2E).
ALLOCENTRIC CONDITION. Performance in this condi-
tion strikingly contrasted with performance in the pre-
vious viewer-centered condition. In the first task, the
patient correctly described and drew a maplike repre-
sentation of the Place Neuve without omission (see Fig
2D). In the second task, he reported 19 cities between
Geneva and Villeneuve, demonstrating his preserved
topographical knowledge (see Fig 2F).
Discussion
This patient showed pure left representational neglect.
Although mental imagery was preserved for nonspatial
information and long-term and short-term spatial
memory were normal, he omitted the left half of space
when imagining visual scenes. Furthermore, represen-
tational neglect was found only when a vantage point
was imposed. By contrast, when the task instruction
emphasized an allocentric instead of viewer-centered
reference frame, the patient did not show any neglect.
These data show that representational neglect may
present as a first isolated, acute, neuropsychological
symptom after a stroke. In the four previous cases of
pure left representational neglect, neuropsychological
examination was carried out quite late after lesion on-
set (2 years,8 16 months,9 21⁄2 months,10 45 days11).
This delay led some authors to conclude that represen-
tational neglect does not exist as an independent entity
but may rather reflect a difference in recovery rate be-
tween performance in perceptual and mental imagery
tasks.12 Our patient was investigated in the acute phase
and our findings thus provide strong evidence in sup-
port of an initial dissociation between perceptual and
representational neglect.8–11
In addition, these findings also demonstrate dissoci-
ation between two frames of reference (viewer-centered
versus allocentric) in spatial mental imagery. Indeed, in
spite of a clear instruction to imagine looking around
him,14 our patient was unable to describe from mem-
ory both sides of a familiar place when mental repre-
sentation had to be generated in relation to his own
body position in the imagined scene, even though he
did it perfectly when he only used knowledge about
spatial relationships independent of his own body po-
sition. This preservation of topographical knowledge
directly indicates that representational neglect was not
a result of memory impairment but rather a result of a
disorder in mental imagery processes operating in a
body-centered system. These findings thus demonstrate
that an imaginary viewer-centered vantage point can
critically influence representational neglect. However,
whether this reflects a deficit in generating mental im-
ages from memory or an impairment of attentional-
activational mechanisms necessary to scan and verbally
report these mental images14 cannot be distinguished.
Finally, unlike previous case descriptions of pure
representational neglect that were all exhibited after
cortical lesions, MRI in our patient showed a lesion
confined to the right dorsomedial thalamus, suggesting
a critical implication of thalamic structures in mental
imagery when a viewer-centered vantage point is given.
The present findings indicate that the spatial represen-
tational network is not only cortico-cortical but also
cortico-subcortical.19 Separate neural systems may con-
vey distinct spatial frames, respectively using viewer-
centered and allocentric information.20 We conjecture
that the right thalamus, with its reciprocal connections
with cortical areas, may serve as a major relay in the
processing of viewer-centered mental imagery. How-
ever, it remains to be established whether a thalamic
lesion in itself may directly be responsible for represen-
tational neglect, or whether some cortical involvement
Table. Patient Data: Description of a Familiar Place in the
Viewer-Centered Conditiona
Vantage
Points
Verbal Description Drawings
Left
Hemispace
Right
Hemispace
Left
Hemispace
Right
Hemispace
1 0/5 5/6 0/5 4/6
2 0/6 4/5 0/6 3/5
3 1/11 0/11
4 6/11 7/11
aNumber of items reported, according to the four imposed vantage
points and to their distribution in left and right hemispace, refer-
enced to the number of items reported in the allocentric condition.
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caused by remote diaschisis effects are necessary for the
occurrence of such cognitive spatial disorders.19
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Elevated Corticotropin
Releasing Hormone/
Corticotropin Releasing
Hormone-R1 Expression in
Postmortem Brain Obtained
from Children with
Generalized Epilepsy
Wei Wang, MD,1 Kimberly E. Dow, MD,1
and Douglas D. Fraser, MD, PhD1–3
The corticotropin releasing hormone (CRH) system has
been suggested to initiate seizure activity in the develop-
ing brain. However, human data to support this theory is
lacking. In this study, we have demonstrated that the ex-
pression of CRH, CRH-binding protein, and CRH-R1 (a
CRH membrane receptor) were significantly elevated in
cortical tissue obtained from 6 children with generalized
epilepsy (mean age 8.2 6 1.5 years) relative to age-
matched controls (mean age 7.8 6 1.4 years). In contrast,
no significant difference in the expression of CRH-R2
was observed. The advent of CRH-R1 receptor antago-
nists may prove useful as novel anticonvulsants.
Ann Neurol 2001;50:404–409
Corticotropin releasing hormone (CRH) is expressed in
both cortical and limbic structures and is implicated in
seizure genesis during development.1 Stressful events
cause a rapid expression of the CRH gene2 and local
CRH release.3 CRH activates membrane receptors
(CRH-R1 and/or CRH-R2)4 to elicit cellular responses
before being inactivated by the CRH-binding protein
(CRH-BP).5 While low concentrations of CRH cause
moderate neuronal excitation, excessive CRH receptor
stimulation causes overt seizure activity.6,7 Conversely,
increased CRH expression is observed in animal mod-
els following seizure activity precipitated by either elec-
trical stimulation8 or kainic acid administration.9 In-
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creased CRH immunoreactivity is also observed in an
epileptic rat strain exhibiting spontaneous tonic-clonic
seizures.10 Upregulation of the CRH system may there-
fore precipitate seizure activity or represent an adaptive
response supporting ongoing epileptogenesis. In young
animals, CRH-induced excitation is mediated specifi-
cally by CRH-R1.11 The advent of appropriate thera-
peutic agents to maintain the CRH system at a re-
duced level of activity (ie, CRH-R1 receptor
antagonists)4 may therefore prove useful as novel anti-
convulsant medication.
While numerous animal studies have implicated the
CRH system in seizure genesis, no human data exist to
corroborate these findings. The aim of this study,
therefore, was to determine whether alterations in the
brain CRH system are associated with epilepsy in chil-
dren. To this end, we have measured mRNA (RT-
PCR) and protein (RIA) levels in postmortem brain
obtained from children with generalized epilepsy and
age-matched controls. More specifically, we examined
the relative cortical expression levels of CRH, CRH-
BP, CRH-R1, and CRH-R2.
Materials and Methods
Postmortem brain was obtained from the Brain and Tissue
Bank for Developmental Disorders, in contract to the
NICHD. Tissue samples consisted of hemicoronal sections
of frozen cortex, neuronal layers I to VI. Inclusion criteria
for the postmortem tissue samples included the availability of
frozen cortical tissue, a postmortem interval #36 hours, a
documented medication list, and a detailed medical examin-
er’s report. Postmortem tissue samples were excluded if age-
matched controls were not available or if systemic steroids
were administered prior to the time of death. All experiments
were performed blind with regard to the patient status.
Total RNA was isolated from thawed cortical tissue by the
acid guanidinum thiocyanate-phenol-chloroform method
and reverse transcribed with AMV reverse transcriptase (Pro-
mega). An aliquot of reverse transcription mixture (2.0ml)
was amplified by PCR for 30 cycles with the following cycle
parameters: 94°C, 1 minute; 55°C, 1 minute; 72°C, 2 min-
utes. Kinetic studies of each gene were performed to give a
linear range of amplification before semiquantitative analysis.
Photographs of the gels were scanned and quantitated using
computer-assisted linear scanning densitometer (Digitizer-IM
1280; Matrox, Vienna, Austria). The primers chosen to assess
mRNA were: CRH (360 bp), 59-CAACTTTTTCCGCGT-
GTTGCT-39 and 59-ATGGCATAAGAGCAGCGCTAT-39;
CRH-BP (634 bp), 59-GTTCATTACCATCCACTACGA-39
and 59-CTCCAGCTGACGATACTCAAA-39; CRH-R1 (476
bp), 59-ACAAACAATGGCTACCGGGAG-39 and 59-
ACACCCCAGCCAATGC AGAC-39; CRH-R2 (615 bp),
59-TGTGGAAGGCTGCTACCTG-39 and 59-GTCTGC-
TTGATGCTGTGGAA-39; b-actin (340 bp), 59-CAAGA-
GATGGCCACGGCTGCT-39 and 59-TCCTTCTGCA-
TCCTGTCGGCA-39. The data were expressed as mean 6
standard error. Differences between groups were compared
by ANOVA (analysis of variance) or by Kruskal-Wallis one-
way analysis of variance on ranks.
Tissue lysates were incubated with rabbit anti-hCRH se-
rum (IgG Corp., Nashville, TN) or CRH-BP antibody 5144
(Dr W. Vale, The Salk Institute, La Jolla, CA) in RIA
buffer, followed by incubation with [125I] Tyro-rat/human
CRH (Du Pont-New England Nuclear, Boston, MA). Goat
anti-rabbit gamma globulin was then added and the samples
were precipitated by centrifugation. The pellet radioactivity
was measured using a gamma counter.
Results
A total of 12 postmortem brain samples (6 generalized
epilepsy, 6 age-matched controls) were analyzed for the
expression of CRH, CRH-BP, CRH-R1 and CRH-R2.
The patient demographics are listed in the Table. The
age difference between a child with epilepsy and their
age-matched control was less than 1 year. The mean
age for patients with generalized epilepsy and age-
matched controls were 8.2 6 1.5 and 7.8 6 1.4, re-
spectively.
Semiquantitative RT-PCR and RIA were used to
measure the expression of CRH mRNA and protein,
respectively. The expression of CRH mRNA (360 bp)
was significantly elevated in all children with epilepsy
relative to their age-matched controls (n 5 6/6;
p , 0.05). In the children with epilepsy, the mean
increase in the expression of CRH mRNA and protein
was 31% and 66%, respectively (Fig 1A-C). Both
semiquantitative RT-PCR and RIA also demonstrated
elevated CRH-BP expression in children with general-
ized epilepsy. A significant elevation in CRH-BP
mRNA (634 bp) was observed in the majority of chil-
dren with epilepsy relative to their age-matched con-
trols (n 5 4/6; p , 0.05). In the children with epi-
lepsy, the mean increase in expression of CRH-BP
mRNA and protein was 51% and 92%, respectively
(see Fig 1D-F).
A significant elevation of CRH-R1 mRNA (476 bp)
was also demonstrated, via semiquantitative RT-PCR,
in the majority of children with epilepsy relative to
their age-matched control (n 5 5/6; p , 0.05). Over-
all, the children with epilepsy expressed 58% more
CRH-R1 mRNA (Fig 2A and B). In contrast,
CRH-R2 mRNA (615 bp) was significantly elevated in
only 1 child with epilepsy relative to their age-matched
control (n 5 1/6; p , 0.05). When the CRH-R2
mRNA values from all postmortem brain tissue were
averaged, the minimal increase in expression was not
statistically significant (see Fig 2C and D). The percent
difference in CRH-R2 mRNA expression between chil-
dren with epilepsy and their age-matched controls was
only 13%.
Discussion
Alterations in the CRH system have been implicated in
seizure genesis during development.1 There have been
no human studies, however, to corroborate this theory.
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The data presented in this paper demonstrates in-
creased expression of CRH, CRH-BP, and CRH-R1 in
brain tissue obtained from children with generalized
epilepsy. The expression levels of CRH-R2 were un-
changed. These findings support the theory that ele-
vated activity of the CRH system may either initiate or
support ongoing seizure activity in children.
CRH production is immediately increased following
stressful events2 and CRH is a potent convulsant in the
developing brain via CRH-R1.6,7 Consequently, it has
been suggested that chronic alterations in the CRH
system secondary to stressful events may underlie some
forms of seizure activity in children.1 Indeed, it is well-
known that fever, hypoxia, hypoglycemia, and trauma
result in rapid increases in CRH production and are
potent triggers for initiating seizure activity in chil-
dren.1 Moreover, repeated stressful events during devel-
opment can result in a chronic elevation of CRH pro-
duction and release.12 Hence, severe or repeated stress
during early development may cause or predispose chil-
dren to epilepsy via elevated CRH activity. Until this
study, however, no human data existed to corroborate
this theory. Our results show a conclusive increase in
both the expression of CRH and CRH-R1 that would
effectively enhance the excitability elicited by the CRH
system, including overt seizure activity. The CRH-BP
mRNA was also elevated, which may serve to regulate
the bioavailability of CRH following CRH-R1 activa-
tion.5 Compensatory increases in CRH-BP gene ex-
pression, which parallel elevated CRH production, are
also observed following kindling-induced seizure activ-
ity in animals.8 Expression of CRH-R2 is statically reg-
ulated during development13 and was unchanged in
this study.
CRH is produced in the nonspiny bipolar neurons
of layers II and III within the cerebral cortex.14 In con-
trast, immunostaining for CRH-R1 shows widespread
distribution throughout layers II to VI.15 CRH-R1 is
localized to the plasma membrane along the soma and
proximal dendrites of neurons,15 an anatomical area
that receives incoming synaptic potentials and performs
signal integration. Hence, CRH is produced and re-
leased locally by spatially restricted interneurons,
thereby modulating the excitability of principle neu-
rons with widespread projections in cortical structures.
Both CRH and CRH-R1 are therefore strategically lo-
calized to synchronize both normal and pathological
levels of neuronal excitability. The CRH-BP is appro-
priately co-localized to structures with prominent im-
munostaining for CRH14 and expressed by both neu-
rons and astrocytes.16
Recent studies suggest that CRH plays an important
role in cognitive and motor development. For example,
injection of CRH into the hippocampus improves
memory retention and induces a long-lasting enhance-
ment of synaptic efficacy.17 In cerebellar tissue, endog-
enous CRH release plays a permissive role in long-term
depression, a form of synaptic plasticity related to mo-
tor learning.18 As many children with seizure disorders
have associated psychomotor delay,19 it is also possible
that chronic overactivity of the CRH system may result
in impaired learning and development. Indeed, pro-
longed CRH-induced seizures in young animals result
in neuronal death and synaptic reorganization;6,7
Table. Patient Demographics of the Children with Generalized Epilepsy and Their Age-Matched Controls
Age
(yr) Sex Seizure Diagnosis Medications Cause of Death
Postmortem
Interval
(hr)
Tissue
Sample
Epilepsy 5 F Tonic-clonic None 3 1 yr Unknown 36 Frontal
Control 4 M None Hanging 19 Frontal
Epilepsy 6 M Tonic-clonic Phenytoin Unknown 21 Parietal
Control 6 M None Drowning 21 Parietal
Epilepsy 6 F Severe myoclonic Valproate Unknown 24 Frontal
Control 7 M Nonea Cardiomyopathy 14 Frontal
Epilepsy 8 F Lennox Gastaut Felbamate,
topiramate
Unknown 8 Frontal
Control 8 F Nonea Arrhythmia 12 Frontal
Epilepsy 9 M Tonic-clonic Phenytoin,
valproate,
lamotrigine
Unknown 17 Parietal
Control 8 M None Trauma 14 Parietal
Epilepsy 15 M Tonic-clonic Phenytoin,
phenobarbital
Unknown 26 Frontal
Control 14 M None Trauma 12 Frontal
aResuscitation medications were given acutely at the time of death (ie, epinephrine, bicarbonate).
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changes that may parallel the cognitive decline ob-
served in severe seizure disorders.19
The results of this paper support the theory that the
CRH system plays a role in seizure genesis during de-
velopment. It is not clear if these findings reflect a
cause of seizure activity or an adaptive response sup-
porting ongoing epileptogenesis. The development of
infantile spasms, for example, is suggested to be caused
by excess CRH production in response to stress-
induced alterations in the brain-adrenal axis during an-
tenatal/perinatal development.20 Indeed, systemic
ACTH administration, which mimics the clinical treat-
ment of infantile spasms, has recently been demon-
strated to downregulate CRH gene expression in cen-
Fig 1. CRH and CRH-BP expression in postmortem cerebral cortex obtained from children with generalized epilepsy and
age-matched controls. (A) Representative RT-PCR gels illustrating CRH (360 bp) bands from postmortem cortical tissue obtained
from a child with epilepsy and their age-matched control. The intensity of the CRH band at 360 bp is greater in the lane labeled
Epilepsy. (B) A plot illustrating the statistically significant (p , 0.05 ) difference in CRH mRNA in postmortem cortical tissue
obtained from children with epilepsy (epilepsy, n 5 6 ) and their age-matched controls (control, n 5 6 ). (C) Another plot
illustrating the statistically significant difference in CRH (p , 0.05 ), as measured by RIA, in postmortem cortical tissue obtained
from children with epilepsy (epilepsy, n 5 6 ) and their age-matched controls (control, n 5 6 ). (D) Representative RT-PCR gels
illustrating CRH-BP (634 bp) bands from postmortem cortical tissue obtained from a child with epilepsy and their age-matched
control. The intensity of the CRH-BP band at 634 bp is greater in the lane labeled Epilepsy. (E) A plot illustrating the
statistically significant (p , 0.05 ) difference in CRH-BP mRNA in postmortem cortical tissue obtained from children with epilepsy
(epilepsy, n 5 6 ) and their age-matched controls (control, n 5 6 ). (F) A plot illustrating the statistically significant (p , 0.05 )
difference in CRH-BP, as measured by RIA, in postmortem cortical tissue obtained from children with epilepsy (epilepsy, n 5 6 )
and their age-matched controls (control, n 5 6 ).
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tral neurons from infant rats.20 It is also feasible that
stressful events during postnatal development may re-
sult in chronic alterations in the CRH system and con-
tribute to other forms of seizure genesis.1 Our data
demonstrate elevated CRH and CRH-R1 expression in
postmortem cerebral cortex obtained from children
with generalized epilepsy, thereby supporting the above
theory. Hence, our findings have important implica-
tions for therapeutics, as recently designed CRH-R1
antagonists4 may demonstrate utility as novel anticon-
vulsant medications.
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We report the first nonsense mutation (G7896A) in the
mtDNA gene for subunit II of cytochrome c oxidase
(COX) in a patient with early-onset multisystem disease
and COX deficiency in muscle. The mutation was hetero-
plasmic in muscle, blood, and fibroblasts from the pa-
tient and abundantly present in COX-deficient fibers, but
less abundant in COX-positive fibers; it was not found in
blood samples from the patient’s asymptomatic maternal
relatives. Immunoblot analysis showed a reduced concen-
tration of both COX II and COX I polypeptides, suggest-
ing impaired assembly of COX holoenzyme.
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Genetic defects leading to isolated cytochrome c oxi-
dase (COX) deficiency have been elucidated only in
the past few years. Several mutations have been found
in all three mtDNA-encoded COX genes1–9 and in nu-
clear genes that affect COX maturation and assembly,
such as SURF-1, COX10, and SCO2.10 COX defi-
ciency is the most commonly recognized respiratory
chain defect in childhood, and clinical presentations
are very heterogeneous, ranging from pure myopathy
to devastating encephalomyopathy.
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In this report, we identified the first stop-codon mu-
tation in the mtDNA-encoded COX II gene in a
3-year-old girl with an early-onset multisystem mito-
chondrial disorder.
Case Report
The 3-year-old propositus was normal at birth but had psy-
chomotor delay and failure to thrive since age 3 months.
Examination at age 11 months showed short stature, low
weight, microcephaly, skin abnormalities, severe hypotonia,
and normal reflexes. Fundoscopy was consistent with pig-
mentary retinopathy. An electroencephalogram (EEG) was
normal. Electrocardiography showed abnormal repolarization
and echocardiography revealed left ventricular hypertrophy
and thickening of the interventricular wall. Blood lactate was
markedly elevated (4.6mmol/L; normal ,2mmol/L). At age
15 months her symptoms and signs remained similar. Brain-
stem auditory evoked potentials (BAEPs) were decreased in
amplitude and latency. Brain MRI showed agenesis of corpus
callosum and cortico-subcortical atrophy. Examination at age
2 years, including brain MRI and cardiological investiga-
tions, showed similar findings to those observed previously.
Blood lactate levels were very increased (5.9mmol/L). A re-
cent clinical evaluation at age 3 years showed that she still
failed to thrive and revealed marked hypotonia without pe-
ripheral hypertonia, microcephaly, mild limitations of eye
movements, pigmentary retinopathy, and concentric hyper-
trophic cardiomyopathy with normal left ventricle function.
EEG was normal, but during sleep there were occasional
bursts of slow waves and isolated spikes. Blood lactate was
5.4mmol/L. Overall, the clinical course has remained stable
for the past year. A muscle biopsy was performed at age 11
months. The family history is negative for neuromuscular
disorders and there is no parental consanguinity.
Muscle Histochemistry and Biochemistry
Histochemical analysis of serial frozen muscle sections was
performed as described.11 The activities of the respiratory
chain complexes were performed in muscle homogenates as
described previously12 and referred to that of citrate synthase
(CS) to correct for mitochondrial volume.
Immunoblot analysis of equal amounts of total cell pro-
tein from muscle cells was performed as described else-
where.13 Proteins were probed with antiserum against COX
II and COX I subunits, ND1 subunit, and the beta subunit
of F1-ATP synthase, and detected with the ECL kit (Amer-
sham).
Molecular Genetic Investigations
We sequenced the 22 mitochondrial tRNA genes as well as
the three COX genes as described.14 Mitochondrial DNA
from muscle, blood, and fibroblasts of the proband and
blood from 2 maternal relatives was amplified using poly-
merase chain reaction (PCR) and sequenced in an ABIPrism
310 DNA sequencer and the cycle dye terminator DNA se-
quencing kit of Applied Biosystems (Perkin Elmer-Applied
Biosystems, Foster City, CA).
To screen for the novel G7896A mutation we used prim-
ers corresponding to nt positions 7,750–7,771 (forward) and
8,349–8,329 (backward)15 to PCR-amplify a 599-bp frag-
ment. In the wild-type mtDNA, there is a restriction site for
the endonuclease Sca I, yielding fragments of 336 and 263
bp. The mutant sequence creates an additional restriction
site for the endonuclease Sca I within the 263 bp fragment,
yielding products of 148 and 115 bp. To quantitate the pro-
portion of mutant mtDNA, a-P32 deoxyadenosine triphos-
phate was added in the last PCR cycle.16 Digested PCR
products were run through a 10% nondenaturing polyacryl-
amide gel and subjected to autoradiography (Fig 1A and B).
Single-muscle fibers were isolated from 30-mm-thick cry-
ostat cross section after COX staining. Selected normal and
abnormal (ie, COX deficient) muscle fibers were processed as
reported17 and subjected to PCR-RFLP analysis as described
above.
Results
Histochemical examination of the muscle biopsy re-
vealed an even reduction of COX activity but showed
no COX-negative fibers. About 40% of the muscle fi-
bers showed normal COX staining. SDH was normal,
and no ragged-red fibers (RRF) were identified (Fig 2A
and B). Biochemical analysis of muscle homogenate re-
vealed a single defect of COX activity, representing
13% of normal control values (5.2nmol/min/mg pro-
tein/CS; normal value 41 6 10), whereas all other re-
spiratory chain complexes were normal.
Genetic analysis revealed the presence of a novel
G7896A transition in COX II gene (see Fig 1B). PCR-
RFLP analysis showed that in the proband the muta-
tion was heteroplasmic in muscle (76%), blood (67%),
and fibroblasts (60%; not shown) from the patient, but
it was not detectable in blood from her mother or her
sister (see Fig 1A). The mutation was not present in 30
patients with other mitochondrial diseases, with or
without known point mutations, and in 80 normal
controls.
Single-muscle fiber analysis showed that the mutant
load in COX-deficient fibers (n 5 9; 70.8 6 8.1%)
was significantly higher than that in COX-positive fi-
bers (n 5 10; 17.6 6 17.8%; p , 0.0001, Mann-
Whitney U test) (see Fig 1B and 2C).
Immunoblot analysis revealed a 53% reduction
(53 6 5%; n 5 5, p , 0.001, Mann-Whitney U test)
of COX II polypeptide and a 48% reduction (48 6
4%; n 5 5; p , 0.001, Mann-Whitney U test) of
COX I polypeptide compared to controls but failed to
demonstrate the presence of truncated COX II
polypeptides (Fig 3).
Discussion
The 3-year-old propositus showed a clinical phenotype
whose most prominent features were early onset hypo-
tonia, psychomotor delay, and marked lactic acidosis.
In addition, she had failure to thrive, mild hypertro-
phic cardiomyopathy, and pigmentary retinopathy.
Muscle histochemistry revealed abundant COX-
deficient fibers, albeit there were neither COX-negative
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fibers nor RRF, and biochemical analysis showed a
profound defect of COX activity. This prompted us to
sequence the three mtDNA-encoded COX genes,
which revealed a novel G7896A nonsense mutation in
the COX II gene (see Fig 1C) that is predicted to cause
premature termination of the translation, with a loss of
123 amino acids at the C-terminus of COX II. Several
lines of evidence support the pathogenicity of this mu-
tation. First, it was heteroplasmic in muscle, blood,
and fibroblasts of the patient, a feature commonly as-
sociated with pathogenic mtDNA mutations, and espe-
cially nonsense ones. Second, it was absent in 110 nor-
mal and disease control individuals. Third, it correlated
well with the marked biochemical defect (ie, isolated
COX deficiency and reduction in COX II polypeptide)
found in muscle. Moreover, single-fiber PCR studies
clearly demonstrated a significant correlation between
mutant-load level and COX activity in individual mus-
cle fibers.
In the proband’s muscle, which contained 76% mu-
tant genomes, COX activity was decreased in many fi-
bers, but there was no COX-negative fiber. These find-
ings suggest an even distribution of mutant load in
COX-deficient fibers, which was confirmed by single-
fiber PCR analysis. We did not observe any RRF or
signs of mitochondrial proliferation in the patient’s
muscle, but given the early age of the patient we can-
not rule out the possibility that COX-negative fibers or
RRF, or both, may appear later in muscle biopsy.
Although we could analyze only muscle, blood, and
cultured cells from our patient, the multisystemic na-
ture of her disease suggests that the G7896A mutation
is also present in other tissues, including CNS and
heart. A possible explanation for the lack of muscle
Fig 1. (A) PCR-RFLP analysis for the G7896A mutation. A
599-bp PCR product digested with Sca I results in two bands
(336 bp and 263 bp) if the wild type is present. In the pres-
ence of the mutation, the 263-bp frgament is cleaved into two
fragments (148 bp and 115 bp). Mutant DNA was detected
in the patient’s muscle, blood, and fibroblasts (not shown), but
not in blood of her mother or sister. Molecular sizes are indi-
cated to the left of the gel. PM 5 patient9s muscle; PB 5
patient9s blood; MB 5 mother9s blood; SB 5sister9s blood.
(B) On single-fiber PCR analysis, the mutational load was
greater in COX-deficient fibers than in COX-positive fibers.
Molecular sizes are indicated to the right of the gel. (C) Chro-
matogram from fluorescent DNA sequencing. Asterisk repre-
sents the heteroplasmic G-to-A transition at position 7,896 in
mtDNA COX II gene.
Fig 2. Histochemical reactions on serial muscle sections, for
(A) SDH and (B) COX. SDH activity was normal. COX
activity was reduced in many fibers. Arrow indicates one Type
I fiber with reduced COX activity. (C) Proportion of the
COX II G7896A mutation in single muscle fibers. The
median proportion of mutant mtDNA in each fiber type is
indicated by a horizontal line. The mean 6 SD is shown
below. The differences between COX-positive and COX-
defective fibers were highly significant (p , 0.0001; Mann-
Whitney U test).
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symptoms at age 3 years is that at such an early age the
oxidative dysfunction is not severe enough to result in
muscle phenotypic expression. Although the patient re-
cently developed mild ophthalmoparesis, more promi-
nent muscle symptoms (ie, exercise intolerance, limb
muscle weakness, or both) may become apparent later
in life. Consistent with this possibility, most patients
with exercise intolerance, muscle weakness, or both,
harboring a pathogenic mutation in the mtDNA-
encoded COX genes, were diagnosed during childhood,
adolescence, or even adulthood.1–9 In fact, among the
patients with mutations in mtDNA COX genes docu-
mented so far, this is the one with the earliest reported
onset and is also the first one reported with cardiomy-
opathy and a lesser involvement of muscle.
Immunoblot analysis demonstrated a similar reduc-
tion of both COX II and COX I proteins. These data
bolster the concept that mutations in the mtDNA-
encoded COX genes can impair assembly of the COX
holoenzyme.5,8,9 The lack of truncated COX II pep-
tides may indicate that they are rapidly degraded or
may represent deletion of the antibody binding site on
COX II polypeptide.
The encephalopathy and hypertrophic cardiomyopa-
thy observed in our patient resemble those seen in pa-
tients with mutations in the nuclear-encoded SCO2
gene,10,18,19 although the latter usually show a more se-
vere cardiomyopathy and a downhill clinical course.
These clinical similarities may be the result of some
common pathogenetic mechanism. A disruption in the
SCO2 protein could impede the incorporation of Cu to
the CuA center of COX II polypeptide, as suggested by
recent studies in both human and yeast.19,20 We suggest
that, as a result of the G7896A mutation, the loss of the
large hydrophobic domain of the COX II polypeptide
that harbors the docking site for the CuA center could
likely result in a lack of incorporation of Cu to the
structure of the protein. The differences in clinical sever-
ity may be accounted for by the presence of significant
amounts of wild-type COX II protein in tissues of our
patient, as shown by immunoblot studies in muscle.
In our patient the mutation seemed to be sporadic,
as we did not find it in blood from any maternal rel-
ative examined. Therefore, it is likely that the mutation
arose as a spontaneous event either during oogenesis or
in early embryogenesis, as suggested by the fact that it
was present in multiple tissues with different embryo-
logical derivation.
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Ocular Flutter Associated
with a Localized Lesion in
the Paramedian Pontine
Reticular Formation
Fred Schon, FRCP,1 Timothy L. Hodgson, PhD,2
Dominic Mort, MRCP,2 and Christopher Kennard, FRCP2
Ocular flutter is a rare horizontal eye movement disorder
characterized by rapid saccadic oscillations. It has been
hypothesized that it is caused by loss of “pause” neuronal
inhibition of “burst” neuron function in the paramedian
pontine reticular formation (PPRF); however, there have
been no imaging studies confirming such anatomical lo-
calization. We report the case of a woman with an acute
attack of multiple sclerosis associated both with ocular
flutter and a circumscribed pontine lesion, mainly involv-
ing the PPRF on magnetic resonance imaging. As she re-
covered from the attack, both the midline pontine lesion
and the ocular flutter dramatically improved. This case is
the first clear evidence that at least some cases of ocular
flutter are due to lesions involving the PPRF.
Ann Neurol 2001;50:413–416
In 1954, Cogan first used the term “ocular flutter”1 to
describe a rare disorder of horizontal eye movements
characterized by rapid short bursts of synchronous back
to back horizontal oscillatory movements usually seen
in the primary position of gaze. Since then, there have
been about 50 reports, usually single cases or small se-
ries, linking the phenomenon to a wide variety of
brainstem and cerebellar conditions, but perhaps most
frequently associated with parainfectious states,2 eg, as
after enteroviral infection.3 Other reported cases in-
clude cerebral malaria,4 cyclosporine treatment,5 and
meningitis.6 It is perhaps surprising that there are no
reported cases in which there has been a clear anatom-
ically localized lesion linked to ocular flutter. We de-
scribe a young woman with a definite relapse of her
multiple sclerosis (MS) who developed prominent oc-
ular flutter associated with a small focal lesion in the
brainstem on magnetic resonance imaging (MRI).
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Case Report
A 40-year-old Caucasian woman presented initially in 1997
with an episode of tingling mostly below her waist that lasted
2 weeks, followed in 1999 by a second episode of persistent
numbness in her hands and feet without any major abnormal
neurological signs. There was some slow improvement over a
few months, but she again presented with a third episode in
June of 2000, complaining of a 2-week history of unsteadi-
ness on walking associated with an awareness that her eyes
were jumping and vague feelings of double vision as well as
urgency of micturition. On examination, she had mild gait
ataxia but normal deep tendon reflexes and flexor plantar
responses. The main finding was prominent ocular flutter
without any obvious ophthalmoplegia or nystagmus. She was
diagnosed as having clinically definite relapsing and remit-
ting MS and treated with a 3-day course of intravenous
methyl prednisolone.
Her routine blood tests were all normal; cerebrospinal
fluid examination was not carried out, but her brain MRI
scan showed multiple small periventricular lesions typical of
MS radiating from the margins of the lateral ventricles and
involving the anterior corpus callosum. In the posterior fossa,
there was a single prominent small midline lesion just below
the dorsal surface of the pons estimated to be 6mm in length
(Fig 1A and B). Reference to the MRI atlas by Kretschman
and Weinrich7 confirmed this lesion to be at the level of the
sixth nerve nuclei and to be virtually exactly occupying the
position of the paramedian pontine reticular formation
(PPRF). There were other far less obvious small areas of ab-
normal signal in the posterior fossa, including two in the left
cerebellar hemisphere, one each in the right cerebellar hemi-
sphere and the superior medulla.
Some weeks after the patient’s acute presentation and after
her main symptoms had started to subside, the patient
agreed to have her eye movements recorded using a previ-
ously described8 infrared tracking method with a sample rate
of 500Hz. These recordings confirmed the rapid back-to-
back saccadic oscillations typical of ocular flutter as shown in
Figure 2. They also confirmed the presence of otherwise nor-
mal eye movements. The patient has continued to improve
with minimal persistent gait ataxia and occasional episodes of
ocular flutter.
The patient had a second brain MRI scan 8 months after
the original one, in which the almost complete disappearance
of the midline pontine lesion in the region of the PPRF was
observed; a new lesion, however, was noted in the right cer-
ebellar hemisphere.
Discussion
In 1979, Zee and colleagues studied a single patient
with ocular flutter9 and related their findings to what
was known about the anatomy and physiology of sac-
cade generation in the monkey. They wrote a paper
titled “A Hypothetical Explanation of Saccadic Oscil-
lations” in which they proposed that “pause” neurons
normally prevent saccadic oscillations during fixation
by inhibiting “burst” neuron firing and that this mech-
anism is disturbed in ocular flutter. They later pro-
posed a similar disturbance in both voluntary10 and
blink-induced saccadic oscillations.11 They hypoth-
esized that the anatomical site involved in this group of
eye movement disorders, which also includes opsoclo-
nus, would be in the medial region of the PPRF, which
is the human equivalent of the pontine raphe interposi-
tus nucleus (RIN), in which pause neurons are located
in the monkey.12 In humans, it lies adjacent to the
midline in the upper pons at the level of the sixth
nerve nucleus, but slightly ventral to it. However, ex-
perimental lesions of the omnipause region with exci-
totoxins caused slow saccades rather than oscillations.
One possible explanation is that burst neurons may
also have been affected.13 Furthermore, Ridley and col-
leagues failed to detect any changes in the human ho-
mologue of the RIN at the light microscopic level in
their postmortem study14 of 2 cases of paraneoplastic
opsoclonus. It is important perhaps to point out that
in their first case there were striking changes seen in
the inferior olivary nucleus. These may be nonspecific,
as such changes have also been reported in cases of
paraneoplastic encephalomyelitis without opsoclonus,16
but other authors have suggested the cerebellum is the
likely anatomical site causing opsoclonus.17,18
In contrast, a more recent postmortem study of a
single patient who died 3 years after developing ataxia,
opsoclonus, dementia, and a peripheral neuropathy,
did show conspicuous changes in the PPRF with neu-
ronal loss, perivascular lymphoid cuffing, and florid as-
trogliosis.16 It was not possible to be certain which
classes of neurons were lost within the PPRF. This pa-
tient also had severe Purkinje cell loss in the cerebel-
lum. No underlying malignancy was found, though she
had high titers of the anti-Ri antibody.
This paper therefore offers perhaps the first clear-cut
evidence linking ocular flutter to the region of the
PPRF. The single, small, anatomically remarkably dis-
crete lesion seen on MRI is located exactly in the re-
gion of the PPRF. The patient’s lack of sixth nerve
palsies or internuclear ophthalmoplegia further under-
lies its extremely discrete anatomical localization. It
seems very unlikely that the other far less prominent
posterior fossa lesions seen on the MRI scan were re-
sponsible for the patient’s ocular flutter for 2 reasons:
First, similar widespread lesions are often seen in cases
of MS but have not been associated with ocular flutter,
despite careful studies trying to correlate eye movement
disorders with MRI changes;19 and second, there was a
clear correlation between the clinical improvement in
the patient’s ocular flutter and the similar improve-
ment seen in the midline MRI lesion in the region of
the PPRF on the repeat MRI scan.
The only comparable case report is by Averbuch-
Heller and colleagues, in which they described a pa-
tient (who developed macrosaccadic oscillations 5 years
after a head injury) in whom there was an MRI lesion
in the right side of the pons extending upward from
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the level of the sixth nerve nucleus into the tegmentum
and basis pontis. It was proposed that the eye move-
ment abnormality was caused by damage to the adja-
cent omnipause neuron projections.20
In conclusion, this case provides probably the most
clear-cut evidence to date in support of the hypothesis
linking ocular flutter to lesions in the PPRF. It does
not explain why so many earlier cases have not shown
a similar anatomical lesion, and it remains possible that
there could be more than one anatomical site associ-
ated with disorders involving saccadic oscillations.
C.K., D.M., and T.H. are supported by the Wellcome Trust.
F.S. thanks Listerbestcare MRI unit for support with this study.
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